In-House, Agency, or Hybrid Programmatic for Pharma?
A total-capability comparison of in-house, agency, and hybrid programmatic models for pharma, including governance, talent, continuity, and cost.
The short answer
Pharma brands periodically ask whether they should bring programmatic in-house, keep it with an agency, or split the work. The debate often focuses on fees. Fees matter, but they are rarely the deciding factor. The better comparison looks at total capability: strategy, execution, data governance, talent, continuity, and control.
Three models
Agency-led. The agency plans, buys, optimizes, and reports. The brand sets strategy and approves plans.
In-house. The brand employs the team and holds the DSP contracts. External partners provide data, technology, and specialist services.
Hybrid. The brand holds the DSP seat and data relationships; the agency or a specialist provides execution and strategy support. Many variations exist.
Comparison
| Factor | Agency-led | In-house | Hybrid |
|---|---|---|---|
| Control over data and seats | Lower | Highest | High |
| Transparency of costs | Depends on contract | Highest | High |
| Access to specialist talent | High | Depends on hiring | Moderate to high |
| Continuity when people leave | Agency absorbs | Brand absorbs | Shared |
| Speed of execution | Depends on agency | Can be fastest | Moderate |
| Fixed cost | Lower | Highest | Moderate |
| Cross-brand learning | Agency sees many clients | Limited to own brands | Some |
| Compliance workflow integration | Needs coordination | Easiest | Moderate |
Questions that decide it
- Scale. Is programmatic spend large enough to justify a full team? Small programs rarely are.
- Talent market. Can the brand hire and retain experienced healthcare programmatic people?
- Data strategy. Does the brand want direct control of first-party data and measurement relationships?
- Governance maturity. Does the brand have processes for decisions, escalation, and review? See the operating model guide.
- Risk tolerance. Who absorbs the risk of turnover and errors?
Common transition mistakes
- Moving in-house to save fees without costing talent. Salaries, benefits, training, tools, and management time add up.
- Losing institutional knowledge. The agency team knows why past decisions were made. Document before transitioning.
- Unclear hybrid roles. Hybrid models fail when nobody knows who owns optimization. Write a RACI.
- Underestimating the learning period. Performance often dips during transitions.
Evaluate agencies either way
Even in-house teams use outside specialists. See how to evaluate an agency's capabilities and agency compensation.
Practical takeaway
Build a three-year total cost and capability comparison for each model, including talent, tools, fees, and transition costs. Choose the model that best fits your scale, talent market, and governance maturity, not the one with the lowest headline fee.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.